The originating document has been archived. We cannot confirm the completeness, accuracy, or currency of the content.
Elahere Prices, Coupons, Copay Cards & Patient Assistance
Elahere (mirvetuximab soravtansine) is a member of the miscellaneous antineoplastics drug class and is commonly used for Fallopian Tube Cancer, Ovarian Cancer, and Peritoneal Cancer.
Elahere prices
Get your FREE Drugs.com Discount Card
Save up to 80% off the cost of prescription drugs and OTC medicines valid at over 65,000 pharmacies.
This is a drug discount program, not an insurance plan.
Elahere Coupons, Copay Cards and Rebates
Elahere offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Elahere Copay Assistance Program
Eligible commercially insured patients may pay $0 per dose; patients will be enrolled in the program for 12 months.
- Applies to:
- Elahere
- Number of uses:
- Per 12 month period
Form more information phone: 833-352-4373 or Visit website
Patient Assistance & Copay Programs for Elahere
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: HealthWell Foundation Copay Program
Eligibility requirements:- May have insurance
- Varies
- FDA Approved Diagnosis - See Program Website for Details
- The patient must also be residing in the US.
- This program provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. Also, for those who are eligible for health insurance, but cannot afford the insurance premium, the foundation may be able to help by paying some or all of the medical portion of insurance premiums. The patient is being treated for a specific disease for which funding is available and has insurance that covers the treatment for this disease. Call for most recent medications as the list is subject to change.
- Elahere (mirvetuximab soravtansine-gynx) Injection
More information please phone: 800-675-8416 Visit website
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Elahere (mirvetuximab soravtansine-gynx) Injection
More information please phone: 866-316-7263 Visit website
Provider: ELAHERE Support Services
Eligibility requirements:- Must be uninsured or underinsured
- At or below 600% of FPL
- FDA-approved diagnosis
- Must be a US resident
- Co‑payment assistance, patient support, and patient assistance programs are available for eligible patients.
- Elahere (mirvetuximab soravtansine-gynx) Injection
More information please phone: 833-352-4373 Visit website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
More about Elahere (mirvetuximab soravtansine)
- Elahere consumer information
- Check interactions
- Compare alternatives
- Reviews (10)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español